

This guide provides a structured methodology for calculating the correct Michem Alçı Geciktirici dosage to achieve a target setting time, based on three primary variables: dosage (0.1%–0.8% of gypsum weight), gypsum type (building gypsum, plaster of Paris, high-strength gypsum, or anhydrite), and ambient temperature. Michem Gypsum Retarder works by adsorbing onto the surface of gypsum crystal nuclei, inhibiting crystal growth and hydration reactions to delay the setting and hardening of gypsum — and the relationship between dosage and setting time extension is non-linear, following a diminishing-returns curve that is further modified by gypsum type and temperature.
The practical calculation approach presented here uses a baseline-reference method: establish the unretarded setting time of the specific gypsum source at the application temperature, then apply a retardation factor based on dosage to predict the retarded setting time. For building gypsum (β-hemihydrate) at 20°C with a baseline initial set of 10–15 minutes, a dosage of 0.2% extends set to 35–50 minutes (approximately 3.3× baseline), 0.3% extends to 50–75 minutes (approximately 5× baseline), and 0.5% extends to 90–130 minutes (approximately 8.7× baseline). These figures are modified by gypsum type (α-hemihydrate requires 20–50% higher dosage for equivalent extension; anhydrite requires different consideration due to its naturally slow hydration) and temperature (30°C reduces retarder efficiency by 20–40%, requiring dosage increase).
All calculations must be validated per ASTM C466 (setting time of gypsum) and ASTM C472 (sampling and testing gypsum) under actual project conditions. The methodology provides a starting dosage that minimizes trial-and-error iterations, not a substitute for project-specific verification.
In gypsum product formulation, the retarder dosage is typically determined through iterative trial-and-error: start at an estimated dosage, measure the setting time per ASTM C466, adjust dosage up or down, retest, and repeat until the target setting time is achieved. While this approach works, it is time-consuming — each trial cycle may take 30–60 minutes for mixing, testing, and result interpretation — and it may require 3–5 cycles to converge on the correct dosage, particularly when working with an unfamiliar gypsum source or at a non-standard temperature.
A structured calculation methodology reduces this to 1–2 trial cycles. By starting from a dosage that is calculated to be close to the target, the formulator saves significant R&D time, accelerates product development, and reduces the material waste associated with repeated trial batches. For manufacturers developing new product formulations or adapting existing formulations to new gypsum sources, this efficiency gain is substantial — a formulation that previously took 2 days of trial-and-error can often be completed in half a day.
Beyond efficiency, the calculation methodology also serves an educational purpose. Understanding the non-linear dosage-response relationship, the effect of gypsum type, and the temperature sensitivity of retarder efficiency gives formulators the knowledge to anticipate and diagnose problems. If a formulation that worked at 20°C suddenly shows flash set at 30°C, the formulator who understands the temperature- retarder interaction can immediately identify the cause and calculate the dosage adjustment needed, rather than beginning a new round of trial-and-error.
For quality control in production, the methodology provides a framework for interpreting setting time deviations. If a production batch shows a set time 20% shorter than target, the formulator can calculate whether this is within the expected variation range (gypsum source variation, ambient temperature fluctuation) or indicates a formulation error (retarder under-dosing, incorrect gypsum type). This diagnostic capability reduces production downtime and accelerates root-cause analysis of quality deviations.
The fundamental relationship between Michem Gypsum Retarder dosage and setting time extension is non-linear. The following data establishes the baseline curve for building gypsum (β-hemihydrate) at 20°C, water-gypsum ratio 0.55, setting time measured per ASTM C466:
Dosage (% of gypsum) | Retardation Factor (× baseline) | Initial Set Time (min) | Marginal Extension per 0.1% Increment (min) |
0% | 1.0× | 10–15 | — |
0.1% | 2.0× | 20–30 | 10–15 |
0.2% | 3.3× | 35–50 | 15–20 |
0.3% | 5.0× | 50–75 | 15–25 |
0.4% | 6.7× | 70–100 | 20–25 |
0.5% | 8.7× | 90–130 | 20–30 |
0.6% | 10.7× | 110–160 | 20–30 |
0.7% | 12.7× | 130–190 | 20–30 |
0.8% | 14.7× | 150–220 | 20–30 |
Note: Indicative values based on β-hemihydrate building gypsum at 20°C, w/g = 0.55. Retardation factor = retarded set time ÷ baseline set time. Must be validated per ASTM C466 and ASTM C472 under project conditions.
The curve is steepest between 0.1% and 0.3% (where each 0.1% increment adds 15–25 minutes of set time) and begins to plateau above 0.5% (where each increment adds a similar absolute amount but the proportional increase diminishes). Below 0.1%, the retardation effect is minimal and inconsistent.
The baseline curve above applies to building gypsum (β-hemihydrate). Other gypsum types require correction:
Gypsum Type | Baseline Set (min, no retarder) | Correction Factor | Gerekçe |
Building gypsum (β-hemihydrate) | 8–15 | 1.0 (reference) | Standard baseline |
Plaster of Paris (β-hemihydrate, fine) | 5–10 | 0.8× (less retarder needed) | Higher surface area → more nucleation sites → retarder more effective per unit |
High-strength gypsum (α-hemihydrate) | 15–25 | 1.3–1.5× (more retarder needed) | Denser crystals → fewer nucleation sites per unit mass → retarder less effective |
Anhydrite (CaSO₄) | 60–180+ | 0.5–0.8× (less retarder needed) | Naturally slow hydration; retarder often unnecessary at normal temperatures |
To apply the correction: multiply the baseline dosage (from the dosage-response table) by the correction factor to obtain the adjusted dosage for that gypsum type.
Example: For a target of 50 minutes initial set with high-strength gypsum (α-hemihydrate):
Gypsum hydration and retarder efficiency are both temperature-dependent. Higher temperatures accelerate hydration (reducing baseline set time and reducing retarder effectiveness) and lower temperatures slow hydration (increasing baseline set time and increasing retarder effectiveness):
Sıcaklık | Baseline Set Correction | Retarder Efficiency Correction | Combined Dosage Adjustment |
5°C | ×1.8–2.0 (set much slower) | ×1.5–1.8 (retarder more effective) | Reduce dosage by 40–55% |
10°C | ×1.3–1.5 | ×1.3–1.5 | Reduce dosage by 25–35% |
15°C | ×1.1–1.2 | ×1.1–1.2 | Reduce dosage by 10–15% |
20°C (reference) | ×1.0 | ×1.0 | No adjustment |
25°C | ×0.85–0.90 | ×0.85–0.90 | Increase dosage by 10–15% |
30°C | ×0.6–0.8 | ×0.6–0.8 | Increase dosage by 20–40% |
35°C | ×0.4–0.6 | ×0.4–0.6 | Increase dosage by 50–80% |
40°C | ×0.3–0.5 | ×0.3–0.5 | Increase dosage by 80–120% (or shift to cooler hours) |
Note: Corrections are indicative. The combined effect of temperature on both baseline set and retarder efficiency means the dosage adjustment is approximately the square of the individual corrections. Must be validated per ASTM C466 at the actual application temperature.
In field validation across temperature ranges, the Michem Technical Applications Team has confirmed that the temperature effect is often underestimated by formulators who work primarily at 20°C. A formulation calibrated at 20°C and applied at 35°C may set 40–60% faster than expected — not because the retarder failed, but because both the gypsum hydration kinetics and the retarder’s adsorption efficiency are temperature-dependent.
The following procedure combines the dosage-response curve, gypsum type correction, and temperature correction into a practical calculation method:
Step 1: Determine baseline set time Measure the unretarded initial set time of the specific gypsum source at the application temperature, per ASTM C466.
Example: Building gypsum at 25°C, unretarded initial set = 8 minutes (faster than the 10–15 min reference at 20°C due to temperature).
Step 2: Define target set time Determine the required initial set time based on application requirements.
Example: Machine-applied plaster requires 60 minutes initial set for continuous application.
Step 3: Calculate required retardation factor Retardation factor = Target set time ÷ Baseline set time
Example: 60 min ÷ 8 min = 7.5× retardation factor required.
Step 4: Look up base dosage from dosage-response table From the baseline table (building gypsum, 20°C), find the dosage that gives approximately 7.5× retardation factor.
Example: 7.5× falls between 0.4% (6.7×) and 0.5% (8.7×). Interpolate: approximately 0.45% base dosage.
Step 5: Apply gypsum type correction (if not building gypsum) Multiply base dosage by the gypsum type correction factor.
Example: Using building gypsum → correction factor = 1.0 → no adjustment. Adjusted dosage = 0.45%.
Step 6: Apply temperature correction Adjust for application temperature.
Example: At 25°C → increase dosage by 10–15%. Adjusted dosage = 0.45% × 1.15 = 0.52% → round to 0.50%.
Step 7: Round to practical dosing precision Round to the nearest 0.05% (typical dry-dosing precision).
Example: 0.50% final calculated dosage.
Step 8: Validate through trial Mix a trial batch at the calculated dosage and measure initial set per ASTM C466. If set time is within ±15% of target, the dosage is acceptable. If not, adjust by 0.05%–0.10% and retest.
Example: Trial at 0.50% gives 55 minutes initial set (target: 60 min). Within ±15% (51–69 min range). Acceptable.
Example A: Self-leveling screed at normal temperature
Parametre | Değer |
Gypsum type | α-hemihydrate (high-strength) |
Baseline set (measured at 20°C) | 18 minutes |
Target initial set | 60 dakika |
Required retardation factor | 60 ÷ 18 = 3.3× |
Base dosage (from table, 3.3×) | 0.20% |
Gypsum type correction (α-hemihydrate) | ×1.4 |
Temperature correction (20°C) | ×1.0 |
Calculated dosage | 0.20% × 1.4 × 1.0 = 0.28% |
Rounded | 0.30% |
Sınıf | GR200 or GR300 (both ●●● for self-leveling) |
Example B: Decorative casting in hot weather
Parametre | Değer |
Gypsum type | Plaster of Paris (fine β-hemihydrate) |
Baseline set (measured at 30°C) | 6 minutes |
Target initial set | 60 dakika |
Required retardation factor | 60 ÷ 6 = 10.0× |
Base dosage (from table, 10.0×) | 0.58% |
Gypsum type correction (plaster of Paris) | ×0.8 |
Temperature correction (30°C) | ×1.30 |
Calculated dosage | 0.58% × 0.8 × 1.30 = 0.60% |
Rounded | 0.60% |
Sınıf | GR150 (●●● for prefabricated components) |
Example C: Winter putty application
Parametre | Değer |
Gypsum type | Building gypsum |
Baseline set (measured at 10°C) | 22 minutes |
Target initial set | 40 minutes |
Required retardation factor | 40 ÷ 22 = 1.8× |
Base dosage (from table, 1.8×) | 0.09% |
Gypsum type correction (building gypsum) | ×1.0 |
Temperature correction (10°C) | ×0.70 |
Calculated dosage | 0.09% × 1.0 × 0.70 = 0.063% |
Rounded | 0.10% (minimum practical dosage) |
Sınıf | GR200 (●●● for gypsum putty) |
Note: At very low retardation factors (<2×), the dosage falls near the minimum effective range (0.1%). Below 0.1%, retardation is inconsistent — if the calculated dosage is below 0.1%, either accept a longer set time (more than target) or use no retarder (rely on the naturally slow set at low temperature).
Site trials under EN/ASTM protocols confirm that this calculation methodology produces dosages within ±20% of the experimentally determined optimal dosage in approximately 80% of cases. The remaining 20% — typically involving unusual gypsum sources (very high or low purity) or extreme temperatures (<5°C or >40°C) — require additional trial iterations.
Mülkiyet | Michem Gypsum Retarder (All Grades) |
Marka | Michem |
Ürün | Alçı Geciktirici |
Ana Bileşen | Organik asit kompleksi / Polikarboksilat bazlı polimer |
Görünüş | White to off-white powder (general); Light yellow powder (grades) |
Notlar | GR150, GR200, GR300 (all: bulk density 700±100 g/L, moisture ≤3%) |
Önerilen Dozaj | 0.1%–0.8% of gypsum weight |
pH Değeri (1% çözeltisi) | 5.0-7.0 |
Suda Çözünmeyen Madde | ≤0,5% |
Uyumlu Alçı Tipleri | Yapı alçısı, Paris alçısı, yüksek mukavemetli alçı, anhidrit |
Raf Ömrü | 12 ay (kapalı, kuru koşullarda) |
Paketleme | PE iç astarlı 25 kg dokuma torba; OEM ambalaj mevcuttur |
Quality System | ISO 9001:2015 |
Source: Michem official technical specifications (michemicals.com).
Target Set Time | Building Gypsum (20°C) | Plaster of Paris (20°C) | High-Strength Gypsum (20°C) | Anhydrite (20°C) |
20 min | 0.10% | 0.08% | 0.15% | 0.05%* |
30 min | 0.15% | 0.12% | 0.20% | 0.08%* |
45 min | 0.22% | 0.18% | 0.30% | 0.15%* |
60 min | 0.28% | 0.22% | 0.40% | 0.20%* |
75 min | 0.35% | 0.28% | 0.48% | 0.25%* |
90 min | 0.42% | 0.34% | 0.58% | 0.30%* |
120 min | 0.55% | 0.44% | 0.75% | 0.40%* |
*Anhydrite may not require retarder at normal temperatures; values shown for hot-weather or large-pour conditions.
Note: Starting dosages for 20°C application. For other temperatures, apply the temperature correction factor. Always validate per ASTM C466.
Application Temperature | Multiply Calculated Dosage By |
5°C | ×0.50 |
10°C | ×0.70 |
15°C | ×0.88 |
20°C | ×1.00 |
25°C | ×1.15 |
30°C | ×1.30 |
35°C | ×1.65 |
40°C | ×2.00 |
Adım | Eylem | Detail |
1 | Dozu hesapla | Use the methodology above (Steps 1–7) |
2 | Mix trial batch | Use exact formulation including all additives; weigh materials precisely |
3 | Measure initial set | Per ASTM C466 (Vicat apparatus) at application temperature |
4 | Compare to target | If within ±15% of target → accept; if outside → adjust and retest |
5 | If set time too short | Increase dosage by 0.05%–0.10%; retest |
6 | If set time too long | Decrease dosage by 0.05%–0.10%; retest |
7 | Document final dosage | Record gypsum source, batch, temperature, and validated dosage for QC reference |
8 | Establish QC range | Set upper/lower dosage limits (±0.05% of validated dosage) per ISO 9001:2015 |
Kontrol et | Yöntem | Acceptance Criterion |
Baseline set time (no retarder) | ASTM C466 | Measured and recorded for each gypsum source |
Retarded set time | ASTM C466 | Within ±15% of target |
Set time ratio (final/initial) | ASTM C472 | 1.5–2.5× (consistent hydration) |
Strength verification | ASTM C472 / EN 13279-1 | ≥90% of unretarded control at 28 days |
Batch reproducibility | ISO 9001:2015 sampling | Set time CV ≤15% across batches |
Temperature monitoring | Thermometer at mixing station | Recorded at each batch; dosage adjusted per temperature table |
In approximately 80% of cases, the calculated dosage produces a setting time within ±20% of the target on the first trial. The remaining cases typically involve unusual gypsum sources (very high or low purity, unusual fineness) or extreme temperatures. A second trial with 0.05%–0.10% dosage adjustment almost always converges on the target. The methodology significantly reduces the number of trial iterations compared to unstructured trial-and-error.
At higher dosages (above 0.5%), the retarder molecules saturate the available crystal nuclei surfaces. Additional retarder has fewer new nuclei to adsorb onto, so the marginal setting time extension per unit of additional dosage decreases. This is also why dosages above 0.8% are not recommended — the additional retardation is minimal and the risk of over-retardation (excessively slow set, strength reduction) increases disproportionately.
Michem HPMC (water retention) and MikaVAE® RDP (polymer film) do not significantly interact with the retarder’s mechanism and do not require dosage adjustment. However, if the formulation includes an accelerator (e.g., ground gypsum dihydrate, potassium sulfate), the retarder dosage may need to increase to compensate — typically by 0.05%–0.15% depending on accelerator dosage. Always test the complete formulation per ASTM C466, not just the gypsum + retarder binary system.
For blended gypsum systems, use the weighted average of the component correction factors. For a 70:30 blend of building gypsum (correction 1.0) and anhydrite (correction 0.65), the blend correction factor = (0.70 × 1.0 + 0.30 × 0.65) = 0.895. Apply this to the base dosage. Always validate blends per ASTM C466, as blend hydration kinetics can be non-linear relative to component proportions.
If the calculation yields a dosage above 0.8%, the target setting time is likely too long for the given gypsum type and temperature combination. Options include: (1) reduce the target setting time (accept a shorter working period); (2) switch to a gypsum type with naturally slower set (e.g., from plaster of Paris to building gypsum, or from β-hemihydrate to α-hemihydrate); (3) shift application to cooler hours (if temperature is the issue); (4) combine retarder with a coagulation-stabilizing additive (Michem HPMC) that provides some additional working time extension. Do not exceed 0.8% dosage — the additional retardation is minimal and strength loss becomes significant.
Product data:
Standards cited:
Kimler için: Gypsum product formulators, dry-mix mortar R&D engineers, quality control technicians, and technical service engineers who need to calculate or predict gypsum retarder dosage for specific applications, gypsum types, and temperature conditions.
Nasıl üretildi: Performance claims draw on Michem official product specifications (michemicals.com) and established EN/ASTM test protocols. Field-experience observations are drawn from the Michem Technical Applications Team’s gypsum systems R&D work.
Sınırlamalar: The dosage-response curve, gypsum type correction factors, and temperature correction factors are indicative and based on the Michem Technical Applications Team’s experience with typical gypsum sources. Actual performance varies with gypsum source purity, fineness, crystal morphology, water-gypsum ratio, and complete formulation. The calculation methodology provides a reliable starting point (within ±20% in ~80% of cases) but must be validated through ASTM C466 site trials under actual project conditions. This guide does not replace engineering judgment or compliance with local building codes.
Güncelleme politikası: Her yıl veya Michem ürün özellikleri ya da atıfta bulunulan EN/ASTM standartları güncellendiğinde gözden geçirilir.
Michem Gypsum Retarder‘s non-linear dosage-response relationship, combined with gypsum type and temperature effects, makes structured dosage calculation an essential tool for efficient formulation development. The methodology presented here — baseline measurement, retardation factor calculation, dosage lookup, gypsum type and temperature correction, and ASTM C466 validation — reduces trial iterations from 3–5 to 1–2 in most cases, accelerating product development and reducing material waste. By understanding and applying the correction factors for α-hemihydrate (1.3–1.5×), plaster of Paris (0.8×), anhydrite (0.5–0.8×), and temperature (from ×0.50 at 5°C to ×2.00 at 40°C), formulators can reliably predict setting time across the full range of Michem Gypsum Retarder’s 0.1%–0.8% dosage range and all compatible gypsum types. With consistent physical properties (bulk density 700±100 g/L, moisture ≤3%, pH 5.0–7.0) and ISO 9001:2015 manufacturing quality, Michem Gypsum Retarder delivers the predictable performance that makes accurate dosage calculation possible.

Ben Tinna, 15 yıldır selüloz eter sektöründe çalışıyorum. Yazımı sizlerle paylaşmaktan memnuniyet duyarım. Eğer iyi fikirleriniz varsa, lütfen bana bildirin.
En son fiyat teklifi için veya numune testi talep etmek için lütfen benimle iletişime geçin (numunelerimiz ücretsizdir ve nakliye dahildir).
Sorularınız 6 saat içinde yanıtlanacaktır. Size özel bir fiyat teklifi alabilmek için lütfen tesisinizin türünü ve aylık hacminizi belirtin.
Size en kısa sürede profesyonel çözümler sunacağız!
Hindistan'dan gelen talepler 4 saat içinde yanıtlanmaktadır. Size özel bir teklif alabilmek için lütfen tesisinizin türünü ve aylık hacminizi belirtin.